Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01606280|
Recruitment Status : Completed
First Posted : May 25, 2012
Last Update Posted : January 22, 2014
|Condition or disease|
- How does age at diagnosis affect prognosis in primary amyloidosis?
- How do lab values at diagnosis such as Creatinine, AST/ALT, total serum protein, serum gamma globulin/immunoglobulin levels affect prognosis in primary amyloidosis?
- How does degree of organ involvement/number of organs involved affect prognosis in primary amyloidosis?
- How does initial treatment affect prognosis in primary amyloidosis?
4. How do the specifics the stem cell transplant protocol affect prognosis in primary amyloidosis?
|Study Type :||Observational|
|Actual Enrollment :||400 participants|
|Official Title:||Reporting of Amyloidosis Stem Cell Transplantation Outcomes|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||June 2013|
- Survival [ Time Frame: up to 8 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01606280
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|